Sylvester researchers identify neutrophils as major factor in treatment resistance of pancreatic cancer

Ci4CC’s 24th Symposium & Workshop set to focus on precision oncology powered by data intelligence

Chaired by the University of Miami Sylvester Comprehensive Cancer Center, the 24th Cancer Centers Informatics Society (Ci4CC) Symposium will convene the nation’s leading designated and community cancer centers with a central focus on advancing precision oncology.

September 26, 2025

Vol.51 No.35

By Stephen D. Nimer

Funding Opportunities

Project Purple announces research grant to sustain pancreatic cancer studies that have been disrupted by federal funding policy changes

Project Purple, a national nonprofit dedicated to empowering the fight against pancreatic cancer, is launching the Pancreatic Cancer Research Recovery Support Grant. The initiative provides up to two years of bridge or rescue funding for promising pancreatic cancer research projects that were disrupted due to administrative funding policy changes at major federal agencies such as the NIH, the Department of Defense, or the National Science Foundation.

September 26, 2025

Vol.51 No.35

Clinical Roundup

Oral microbes linked to increased risk of pancreatic cancer

Twenty-seven species of bacteria and fungi, among the hundreds that live in people’s mouths, have been collectively tied to a 3.5 times greater risk of developing pancreatic cancer, according to a study led by NYU Langone Health and its Perlmutter Cancer Center.

September 19, 2025

Vol.51 No.34

Clinical Roundup

Researchers identify key enzyme that pancreatic cancer cells need to obtain vital metabolic nutrients

A team of scientists at Sanford Burnham Prebys and the University of Zurich in Switzerland identified a specific phosphoinositide kinase called PI5P4Kα as critical to supporting the unique demands of pancreatic ductal adenocarcinoma cells.

September 19, 2025

Vol.51 No.34

Clinical Roundup

Off-the-shelf cancer vaccine elicits strong immune response in patients with pancreatic and colorectal cancer

ELI-002 2P, an off-the-shelf cancer vaccine, can trigger powerful and lasting immune responses, and may help prevent or delay cancer recurrence in high-risk patients whose tumors are driven by KRAS mutations, according to a study published in Nature Medicine.

September 05, 2025

Vol.51 No.32

Clinical Roundup

Blocking macropinocytosis changes TME, allows for more effective treatment, preclinical study shows

Blocking macropinocytosis reshapes the tumor microenvironment to be less fibrous and to allow more access to immune cells, according to a preclinical study of pancreatic tumors conducted by scientists at Sanford Burnham Prebys, an NCI-designated Cancer Center.

August 01, 2025

Vol.51 No.30

Sylvester researchers identify neutrophils as major factor in treatment resistance of pancreatic cancer

YOU MAY BE INTERESTED IN

Ci4CC’s 24th Symposium & Workshop set to focus on precision oncology powered by data intelligence

Project Purple announces research grant to sustain pancreatic cancer studies that have been disrupted by federal funding policy changes

Oral microbes linked to increased risk of pancreatic cancer

Researchers identify key enzyme that pancreatic cancer cells need to obtain vital metabolic nutrients

Off-the-shelf cancer vaccine elicits strong immune response in patients with pancreatic and colorectal cancer

Blocking macropinocytosis changes TME, allows for more effective treatment, preclinical study shows

Renew today!

Subscriber content

Never miss an issue!

Login